Pioglitazone improves left ventricular diastolic function in subjects with diabetes

Diabetes Care

Volumn 40, Issue 11, 2017, Pages 1530-1536

  Clarke, Geoffrey D ^a   Solis Herrera, Carolina ^a   Molina Wilkins, Marjorie ^a   Martinez, Sandra ^a   Merovci, Aurora ^a   Cersosimo, Eugenio ^a   Chilton, Robert J ^a,b   Iozzo, Patricia ^c   Gastaldelli, Amalia ^a,c   Abdul Ghani, Muhammad ^a   DeFronzo, Ralph A ^a,b,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^d Texas Diabetes Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHOLESTEROL; GLYCOSYLATED HEMOGLOBIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLUCOSE TRANSPORT; HEART ATRIUM CONTRACTION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE PERFUSION; HEART OUTPUT; HEART STROKE VOLUME; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; BODY MASS; CARDIAC MUSCLE; DIASTOLE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; SYSTOLE;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIASTOLE; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIUM; STROKE VOLUME; SYSTOLE; THIAZOLIDINEDIONES; TRIGLYCERIDES; VENTRICULAR FUNCTION, LEFT;

EID: 85031490199     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-0078     Document Type: Article

References (43)

1. Beckman JA, CreagerMA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-2581
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234
3. Bhuiyan T, Maurer MS. Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep 2011;5: 440-449
4. Diamant M, Lamb HJ, Groeneveld Y, et al. Diastolic dysfunction is associated with altered myocardialmetabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 2003;42:328-335
5. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007;115:3213-3223
6. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015;385:2107-2117
7. DeFronzo RA. Banting Lecture. Fromthe triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
8. van der Meer RW, Rijzewijk LJ, de Jong HW, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation 2009;119:2069-2077
9. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial resonance spectroscopy study. Circulation 2002;116:1170-1175
10. Gastaldelli A, Cusi K, PettitiM, et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 2007;133:496-506
11. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in noninsulin-dependent diabetes mellitus. Evidence formultiple sites of insulin resistance. J Clin Invest 1989;84:205-213
12. BajajM, Baig R, Suraamornkul S, et al. Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2010;95:1916-1923
13. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118
14. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-719
15. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolismin patientswith type 2 diabetesmellitus. Diabetologia 2007;50:1723-1731
16. Schernthaner G, Currie CJ, Schernthaner GH. Do we still need pioglitazone for the treatment of type 2 diabetes A risk-benefit critique in 2013. Diabetes Care 2013;36(Suppl. 2):S155-S161
17. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: The missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-1287
18. Nolan CJ, RudermanNB, Kahn SE, PedersenO, PrentkiM. Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes 2015;64:673-686
19. TaegtmeyerH, Golfman L, Sharma S, Razeghi P, van Arsdall M. Linking gene expression to function: metabolic flexibility in the normal and diseased heart. AnnN Y Acad Sci 2004;1015:202-213
20. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patientswith type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial InmacroVascular Events): A randomised controlled trial. Lancet 2005;366: 1279-1289
21. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L; PROactive Investigators. Impact of peripheral arterial disease in patients with diabetesdresults fromPROactive (PROactive 11). Atherosclerosis 2009;202:272-281
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
23. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003;361:2005-2016
24. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014;2:843-851
25. Kernan WN, Viscoli CM, Furie KL, et al.; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-1331
26. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-263
27. Home P. Safety of PPAR agonists. Diabetes Care 2011;34(Suppl. 2):S215-S219
28. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2017 executive summary. Endocr Pract 2017;23:207-238
29. American Diabetes Association. Standards of medical care in diabetesd2017. Diabetes Care 2017;40(Suppl. 1):S1-S131
30. Hartiala JJ, Mostbeck GH, Foster E, et al. Velocity-encoded cine MRI in the evaluation of left ventricular diastolic function: measurement of mitral valve and pulmonary vein flow velocities and flowvolume across themitral valve. AmHeart J 1993;125:1054-1066
31. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002;51:3020-3024
32. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-E223
33. Lautamäki R, Airaksinen KE, Seppänen M, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: A 16-week randomized, double-blind, placebo-controlled study. Diabetes 2005;54:2787-2794
34. VerbraeckenJ, Van deHeyning P, DeBackerW, Van Gaal L. Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 2006;55:515-524
35. Hermansen F, Ashburner J, Spinks TJ, Kooner JS, Camici PG, Lammertsma AA. Generation of myocardial factor images directly from the dynamic oxygen-15-water scan without use of an oxygen-15-carbon monoxide blood-pool scan. J Nucl Med 1998;39:1696-1702
36. Eldor R, DeFronzo RA, Abdul-GhaniM. In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. Diabetes Care 2013;36(Suppl. 2): S162-S174
37. Hällsten K, Virtanen KA, Lönnqvist F, et al. Enhancement of insulin-stimulated myocardial glucose uptake in patients with type 2 diabetes treated with rosiglitazone. Diabet Med 2004;21: 1280-1287
38. Tsuji T, Mizushige K, Noma T, et al. Pioglitazone improves left ventricular diastolic function and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 2001;38:868-874
39. Pavlov TS, Imig JD, Staruschenko A. Regulation of EnaC-mediated sodium reabsorption by peroxisome proliferator-activated receptors. PPAR Res 2010;2010:703735
40. Guan Y, HaoC, ChaDR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-866
41. Ordu S, Ozhan H, Alemdar R, et al. Pioglitazone improves ventricular diastolic function in patients with diabetes mellitus: A tissue Doppler study. Acta Cardiol 2010;65:401-406
42. Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007;30:387-394
43. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 2003;52:1943-1950